Galectin 3 and its binding protein in rheumatoid arthritis

Arthritis Rheum. 2003 Oct;48(10):2788-95. doi: 10.1002/art.11287.

Abstract

Objective: To characterize the expression pattern and role of galectin 3 and galectin 3 binding protein (G3BP) in rheumatoid arthritis (RA), in comparison with galectin 1, and to explore whether soluble galectin 3 and G3BP, investigated in serum, synovial fluid, or cell culture supernatant, are associated with disease.

Methods: Synovial tissues from patients with RA or osteoarthritis (OA), as well as from healthy controls, were analyzed for galectins 1 and 3 and G3BP by in situ hybridization and immunohistochemistry. Levels of galectin 3 and G3BP in serum and synovial fluid from patients with RA and OA and controls, as well as in cell culture supernatants, were determined by enzyme-linked immunosorbent assay (ELISA). In vitro, the intracellular expression of galectin 3 in RA and OA synovial fibroblasts after modulation with tumor necrosis factor alpha (TNFalpha), interleukin-1beta (IL-1beta), and anti-CD40 monoclonal antibodies was measured by flow cytometry.

Results: In RA, galectin 3 messenger RNA and protein stained throughout the synovial membrane, whereas G3BP was particularly expressed at sites of bone destruction. In contrast, the expression of galectin 1 was not uniform in different RA specimens, and was never found at sites of invasion. In OA and normal synovial tissues, only a small number of cells were positive for galectins and/or G3BP. Galectin 3 was elevated in RA sera and synovial fluids, whereas G3BP was increased in RA synovial fluids only. In RA, serum galectin 3 correlated with C-reactive protein levels, whereas G3BP was associated with joint destruction and/or synovial cell activation as measured by the levels of cartilage oligomeric matrix protein. In vitro, RA synovial fibroblasts showed an increased release of galectin 3 into culture medium, as measured by ELISA, but decreased secretion of G3BP. In RA synovial fibroblasts with low basal expression of galectin 3, TNFalpha increased its intracellular level in a dose-dependent manner. In contrast, IL-1beta or anti-CD40 monoclonal antibodies showed no effect.

Conclusion: Our data indicate that galectin 3 and G3BP are not only involved in inflammation, but also contribute to the activation of synovial fibroblasts. The intracellular accumulation of galectin 3 can be enhanced by TNFalpha. Thus, galectin 3 and G3BP represent novel markers of disease activity in RA.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Arthritis, Rheumatoid / immunology
  • Arthritis, Rheumatoid / metabolism
  • Arthritis, Rheumatoid / physiopathology*
  • Biomarkers
  • C-Reactive Protein / metabolism
  • Carrier Proteins / blood*
  • Carrier Proteins / genetics*
  • Cartilage Oligomeric Matrix Protein
  • Cell Adhesion / immunology
  • DNA Helicases
  • Extracellular Matrix Proteins / metabolism
  • Fibroblasts / cytology
  • Fibroblasts / physiology
  • Galectin 3 / blood*
  • Galectin 3 / genetics*
  • Gene Expression
  • Glycoproteins / metabolism
  • Humans
  • In Vitro Techniques
  • Interleukin-1 / metabolism
  • Matrilin Proteins
  • Osteoarthritis / immunology
  • Osteoarthritis / metabolism
  • Osteoarthritis / physiopathology
  • Poly-ADP-Ribose Binding Proteins
  • RNA Helicases
  • RNA Recognition Motif Proteins
  • RNA, Messenger / analysis
  • Synovial Fluid / metabolism
  • Synovial Membrane / cytology
  • Synovial Membrane / immunology

Substances

  • Biomarkers
  • Carrier Proteins
  • Cartilage Oligomeric Matrix Protein
  • Extracellular Matrix Proteins
  • Galectin 3
  • Glycoproteins
  • Interleukin-1
  • Matrilin Proteins
  • Poly-ADP-Ribose Binding Proteins
  • RNA Recognition Motif Proteins
  • RNA, Messenger
  • TSP5 protein, human
  • C-Reactive Protein
  • DNA Helicases
  • G3BP1 protein, human
  • RNA Helicases